DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00732147

WithdrawnPhase NA

Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

Effects of Pramlintide on Endogenous Production of VLDL-Triglyceride and Glucose in the Post Prandial State in Type 2 Diabetes Mellitus

Asset

Pramlintide

Subcutaneous · Amylin analog

Listed sites

0

Recruiting sites

—

Enrollment

—

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI ≤52•HbA1c ≤10%

Primary endpoint

•Endogenous glucose production

Identifiers

Registered as

NCT IDNCT00732147
Org study IDhp-00044094

Timeline

Milestones

Study first posted2008-08-11estimated
Last update posted2021-07-22actual
Study start2009-04 (month precision)
Primary completion2011-04actual (month precision)
Study completion2011-04actual (month precision)

Assets

Investigational agents

Pramlintide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age20 Years
Maximum age60 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Type 2 DM study participants will be C-Peptide positive (levels > 0.3 nmol/L)
•Receiving insulin, metformin and/or sulfonylurea/glitinide.
•Maintained on stable anti-hypertensive medication.
•BMI < 52 kg/m2.
•T2DM for at least 3 months with HBA1C under 10%.

Exclusion criteria

•Receiving TZDs, exenatide, sitagliptin or pramlintide therapy.
•Receiving medications known to impair gastric emptying, intestinal motility, glucagon release or corticosteroids.
•Triglyceride levels > 400 mg/dl.
•BMI > 52 kg/m2.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
1
Cardiometabolic biomarkers
1

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

Endogenous glucose production

Time frame:18 hours

descriptive

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

Endogenous VLDL-Triglyceride production

Time frame:18 hours

Triglycerides, change

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.